Sell-the-News Hits MoonLake: Strong Sonelokimab Data Fail to Impress vs. Bimzelx
Strong results matched but did not beat Bimzelx, triggering sell-the-news.
Already have an account? Sign in.
Strong results matched but did not beat Bimzelx, triggering sell-the-news.
FDA review papers reveal encouraging Week 52 eGFR findings (+5.2 placebo-adjusted) for TRUTAKNA in primary IgA nephropathy patients.
Key reason: rapid shift to >90% AI revenue and exclusive position in high-power reliability testing for advanced chips.
Backlog hits $1.76B (4.5x book-to-bill), implying ~48% upside despite Q2 miss.